Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Lymphoid 1CNS 1

Conditions

Solitary Fibrous Tumors 1Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Granuloma, Plasma Cell 1Glioma 1Glioblastoma 1

Interventions

Temozolomide 4Specimen Handling 3Magnetic Resonance Spectroscopy 3Paclitaxel 2Gemcitabine 2Filgrastim 2Drug Therapy 2Cognitive Behavioral Therapy 2Blood Specimen Collection 2Azacitidine 2vocimagene amiretrorepvec 1trametinib 1sonidegib 1sargramostim 1ruxolitinib 1rucaparib 1ribociclib 1repotrectinib 1imetelstat 1fludarabine 1epacadostat 1dostarlimab 1depatuxizumab 1ceritinib 1cemiplimab 1cc-486 1carboxyamido-triazole 1acalabrutinib 1abiraterone 1Uncertainty 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × Capsules × Lymphoid × Clear all
NCT04094610 2025-11-19

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
75 enrolled
CNSLymphoidPlasma cellSarcoma

Glioblastoma, Glioma, Granuloma, Plasma Cell, Lymphoma, Neoplasm Metastasis, Sarcoma, Lymphoma, Large-Cell, Anaplastic, Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡